Bendamustine hydrochloride
Code | Size | Price |
---|
TAR-T0095-25mg | 25mg | £105.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0095-1mL | 1 mL * 10 mM (in DMSO) | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0095-50mg | 50mg | £127.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0095-100mg | 100mg | £172.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0095-200mg | 200mg | £244.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0095-500mg | 500mg | £361.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Bendamustine hydrochloride (IC50 of 50 μM) is an alkylating agent associated with DNA damage.
CAS:
3543-75-7
Formula:
C16H22Cl3N3O2
Molecular Weight:
394.72
Pathway:
Apoptosis; Cell Cycle/Checkpoint; DNA Damage/DNA Repair
Purity:
0.9803
SMILES:
Cl.Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl
Target:
Apoptosis; DNA Alkylator/Crosslinker; DNA/RNA Synthesis
References
1. Leoni LM, et al. Clin Cancer Res. 2008, 14(1), 309-317.
2. Schw?nen C, et al. Leukemia. 2002, 16(10), 2096-2105.
3. Konstantinov SM, et al. J Cancer Res Clin Oncol. 2002, 128(5), 271-278.
4. Ackler S, et al. Br J Pharmacol. 2012.
5. Chow KU, et al. Biochem Pharmacol. 2003, 66(5), 711-724.
6. Minbo Zang, et al. Effects of chemotherapeutic agent bendamustine for non-hodgkin lymphoma on spermatogenesis in mice. J Biomed Res. 2017 0(0): 1-12.
7. Zhao X, Wang M Y, Jiang H, et al. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma[J]. Cell Reports. 2021, 34(11): 108870.